Sri Lankan authorities on Friday granted approval for the emergency use of the Oxford-AstraZeneca Covid-19 vaccine, Minister for Pharmaceutical Production and Regulation Channa Jayasumana said.Jayasumana said the National Medicines Regulatory .
Sri Lanka approves Oxford-AstraZeneca Covid-19 vaccine for emergency use
Premium
(REUTERS)
It is unknown when Sri Lanka will be getting the vaccine
After two months during which no community cases were reported, a random test on a factory worker in October led to the detection of a new cluster
Share Via
Read Full Story
Sri Lanka on Friday approved the Oxford-AstraZeneca vaccine for Covid-19 amid warnings from doctors that front-line health workers should be quickly inoculated to stop the system from collapsing.
Minister for Pharmaceutical Production and Regulation Channa Jayasumana said the British vaccine has been approved for emergency use, the first in Sri Lanka, while several other candidates are in the pipeline at the National Medicines Regulatory Authority.
January 22, 2021
Sri Lanka has approved the Oxford-AstraZeneca coronavirus vaccine for emergency use, becoming the first vaccine to get a nod from the country s National Medicines Regulatory Authority (NMRA). Courtesy photo
COLOMBO Sri Lanka has approved the Oxford-AstraZeneca coronavirus vaccine for emergency use, becoming the first vaccine to get a nod from the country s National Medicines Regulatory Authority (NMRA).
Making the announcement, Minister for Pharmaceutical Production and Regulation Channa Jayasumana said: “We believe we will be able to provide it in a few days in Sri Lanka. This is the first time we have given approval for a COVID-19 vaccine in the country,” he said.
The truth behind the rumours on Facia
January, 22, 2021
Alaris Lanka Pvt Ltd conducted a press conference on the 20
th Jan 2021 explaining to media regarding the false rumours been circulated about their brand “Facia Premium” Mr. Tharanga Lanka Weerawardana, Chairman and the Managing Director of Alaris Group of Companies stated that a false letter baring the letterhead of the National Medicine Regulatory Authority and false signature of Dr. Kamal Jayasinghe who is the CEO of the National Medicines Regulatory Authority stating that the product Facia Premium has been banned has been circulated in some print & social media. In response to this, the CEO of NMRA has denied the issuance of such letter and instructed the Director of The Fraud Investigation Bureau to conduct an investigation on priority basis” Further he stated that this the two newspapers who published this news have immediately corrected the same after contacting the NMRA and Sri Lanka Customs. Further Face book h